About Us

Synapto is an early-stage medical technology company transforming Alzheimer's Disease screening through portable EEG and Machine Learning.


Promising Screening in a Challenging Disease Area

Alzheimer's Disease is a devastating, irreversible, progressive brain disorder that slowly destroys memory, cognition, and eventually the ability to complete simple tasks. As the 6th leading cause of death in the United States, it is one of the most expensive diseases, costing close to $259 billion dollars annually in the US. Alzheimer’s disease biology can manifest in the brain up to 10 years prior to patient symptoms, however due to the cost-prohibitive and resource intensive nature of diagnosis, Alzheimer’s disease screening is not routine. Our innovative device moves away from costly neuroimaging diagnostic techniques and qualitative methods of diagnosis to a more robust, affordable, and accessible mode of analysis, a portable Electroencephalogram (EEG) + Artificial Intelligence system.

An Innovation Engineered for Care

Our platform extracts complex mathematical characteristics from a patient’s brainwaves, and by engaging machine learning, decides whether that particular brainwave has signatures of neurodegeneration or is healthy.

Precision Hardware

A portable Electroencephalogram records highly sensitive electrical signals in the brain, which can then be inspected using novel methods of analyses. Recordings like these then allow machine learning models to predict the severity and progression of the disease. For research, Synapto is utilizing portable EEG from OpenBCI and other sources, making our platform unique in that it is more affordable and accessible than current EEG diagnostic measures.


Synapto in the Media

What They Say About Us.

  • Synapto’s project serves as a prime example of how tomorrow’s bioengineers are working today to find solutions to some of the most significant health challenges our society faces.

    Author image
    John Fisher Fischell Family Distinguished Professor and BIOE chair
  • This represents a monumental achievement, not simply for the engineering community, but for the wider world of human health research.

    Author image
    Darryll J. Pines Dean of the Clark School and Nariman Farvardin Professor.
  • I think the device is unique and will prove to be the first line of testing in the future for detection of Alzheimer disease.

    Author image
    Roopal Karia, MD Clinical Professor in Neurology

Meet the Team


Dhruv Patel


Christopher Look


David Boegner
Lead Systems Engineer


Megha Guggari
Lead Software Engineer


Anoop Patel
Lead R&D Engineer